Gastric inhibitory polypeptide receptor (Protein)

Description: A protein in the knowledge graph

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Gastric inhibitory polypeptide receptor 's neighborhood in the knowledge graph.

Submit

Knowledge Graph Assertions

Source	Relation	Target	Evidence
(R)-3-{4-[3-(3-tert-Butylphenyl)-1-(4-cyclohexylphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Gastric inhibitory polypeptide receptor Protein (Entity type)	IC50
(R)-3-{4-[1-(4-Cyclohex-1-enylphenyl)-3-(2,2,4,4-tetrafluoro-4H-benzo[1,3]dioxin-6-yl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Gastric inhibitory polypeptide receptor Protein (Entity type)	IC50
(3S,6S,9S,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54S,57S,66S)-12-((1H-indol-3-yl)methyl)-57-((2S,5S,8S,11S,14S,20S,26S)-26-amino-20-(3-amino-3-oxopropyl)-11-benzyl-2-(carboxymethyl)-8,14-bis((R)-1-hydroxyethyl)-5-(hydroxymethyl)-27-(1H-imidazol-5-yl)-23,23-dimethyl-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazaheptacosanamido)-3-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-ylcarbamoyl)-36-(3-amino-3-oxopropyl)-27,51-bis(4-aminobutyl)-21-benzyl-18-sec-butyl-24,39-bis(2-carboxyethyl)-42-(carboxymethyl)-48-(4-hydroxybenzyl)-54-(hydroxymethyl)-6,9,45-triisobutyl-15,30,33-trimethyl-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,63-nonadecaoxo-66-palmitamido-4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,62-nonadecaazaheptahexacontane-1,67-dioic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Gastric inhibitory polypeptide receptor Protein (Entity type)	EC50
(R)-3-{4-[1-(4-Cyclohexylphenyl)-3-(4-trifluoromethylsulfanylphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Gastric inhibitory polypeptide receptor Protein (Entity type)	IC50
(R)-3-{4-[1-(4-Cyclohexylphenyl)-3-(3,5-dichlorophenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Gastric inhibitory polypeptide receptor Protein (Entity type)	IC50
(3S,6S,9S,12S,15S,18S,21S)-3-((3S,6S,9S,12S,21S)-21-((2R,3S,6S,9S,12S,15S,18S,21S,24S,27S)-15-((1H-indol-3-yl)methyl)-6-(2-amino-2-oxoethyl)-24-benzyl-21-sec-butyl-3-carbamoyl-29-carboxy-2-hydroxy-12-isobutyl-18-methyl-9-(2-(methylthio)ethyl)-5,8,11,14,17,20,23,26-octaoxo-4,7,10,13,16,19,22,25-octaazanonacosan-27-ylcarbamoyl)-9-(3-amino-3-oxopropyl)-3,6-dimethyl-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentaazacyclohenicosan-12-ylcarbamoyl)-21-((2S,5S,8S,11S,17S,20S,23S)-23-amino-17-(3-amino-3-oxopropyl)-8-benzyl-5,11-bis((R)-1-hydroxyethyl)-2,20-bis(hydroxymethyl)-24-(1H-imidazol-5-yl)-4,7,10,13,16,19,22-heptaoxo-3,6,9,12,15,18,21-heptaazatetracosanamido)-12-(4-aminobutyl)-9,18-bis(4-hydroxybenzyl)-15-(hydroxymethyl)-6-isobutyl-5,8,11,14,17,20-hexaoxo-4,7,10,13,16,19-hexaazatricosane-1,23-dioic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Gastric inhibitory polypeptide receptor Protein (Entity type)	EC50
Gastric inhibitory polypeptide receptor Protein (Entity type)	Has isoform Knowledge Graph Relation (Entity type)	UNIPROTKB.ISOFORM:P48546-1 CUI Isoform (Entity type)
(3S,6S,9S,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54S,57S,66S)-12-((1H-indol-3-yl)methyl)-3-(2-((S)-1-(2-amino-2-oxoethylamino)-5-guanidino-1-oxopentan-2-ylamino)-2-oxoethylcarbamoyl)-57-((2S,5S,8S,11S,14S,20S,26S)-26-amino-20-(3-amino-3-oxopropyl)-11-benzyl-2-(carboxymethyl)-8,14-bis((R)-1-hydroxyethyl)-5-(hydroxymethyl)-27-(1H-imidazol-5-yl)-23,23-dimethyl-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazaheptacosanamido)-15,27-bis(3-amino-3-oxopropyl)-51-(4-aminobutyl)-21-benzyl-39-(2-carboxyethyl)-24,42-bis(carboxymethyl)-36-(3-guanidinopropyl)-48-(4-hydroxybenzyl)-54-(hydroxymethyl)-6,9,45-triisobutyl-18-isopropyl-30,33-dimethyl-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,63-nonadecaoxo-66-palmitamido-4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,62-nonadecaazaheptahexacontane-1,67-dioic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Gastric inhibitory polypeptide receptor Protein (Entity type)	EC50
(3S,6S,9S,12S,15S,18S,21S)-3-((3S,6S,9S,12S,21S)-6-((1H-imidazol-5-yl)methyl)-21-((2R,3S,6S,9S,12S,15S,18S,21S,24S,27S)-15-((1H-indol-3-yl)methyl)-6-(2-amino-2-oxoethyl)-24-benzyl-21-sec-butyl-3-carbamoyl-29-carboxy-2-hydroxy-12-isobutyl-18-methyl-9-(2-(methylthio)ethyl)-5,8,11,14,17,20,23,26-octaoxo-4,7,10,13,16,19,22,25-octaazanonacosan-27-ylcarbamoyl)-3-(3-amino-3-oxopropyl)-9-sec-butyl-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentaazacyclohenicosan-12-ylcarbamoyl)-21-((2S,5S,8S,11S,17S,20S,23S)-23-amino-17-(3-amino-3-oxopropyl)-8-benzyl-5,11-bis((R)-1-hydroxyethyl)-2,20-bis(hydroxymethyl)-24-(1H-imidazol-5-yl)-4,7,10,13,16,19,22-heptaoxo-3,6,9,12,15,18,21-heptaazatetracosanamido)-12-(4-aminobutyl)-9,18-bis(4-hydroxybenzyl)-15-(hydroxymethyl)-6-isobutyl-5,8,11,14,17,20-hexaoxo-4,7,10,13,16,19-hexaazatricosane-1,23-dioic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Gastric inhibitory polypeptide receptor Protein (Entity type)	EC50
(4S,7S,10S,13S,16S,19S,22S,25S,28S,31S,34S,37S,46S)-4-((2S,5S,8S,11S,14S,17S,20S,23S,24R)-11-((1H-indol-3-yl)methyl)-20-(2-amino-2-oxoethyl)-5-sec-butyl-23-carbamoyl-24-hydroxy-14-isobutyl-8-methyl-17-(2-(methylthio)ethyl)-3,6,9,12,15,18,21-heptaoxo-1-phenyl-4,7,10,13,16,19,22-heptaazapentacosan-2-ylcarbamoyl)-37-((2S,5S,8S,11S,14S,20S,23R,26S)-26-amino-20-(3-amino-3-oxopropyl)-11-benzyl-2-(carboxymethyl)-8,14-bis((R)-1-hydroxyethyl)-5,23-bis(hydroxymethyl)-27-(1H-imidazol-5-yl)-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazaheptacosanamido)-16-(3-amino-3-oxopropyl)-7,31-bis(4-aminobutyl)-19-(2-carboxyethyl)-22-(carboxymethyl)-28-(4-hydroxybenzyl)-34-(hydroxymethyl)-25-isobutyl-10,13-dimethyl-6,9,12,15,18,21,24,27,30,33,36,43-dodecaoxo-46-palmitamido-5,8,11,14,17,20,23,26,29,32,35,42-dodecaazaheptatetracontane-1,47-dioic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Gastric inhibitory polypeptide receptor Protein (Entity type)	EC50

(R)-3-{4-[3-(3-tert-Butylphenyl)-1-(4-cyclohexylphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
Gastric inhibitory polypeptide receptor
Protein (Entity type)
IC50

(R)-3-{4-[1-(4-Cyclohex-1-enylphenyl)-3-(2,2,4,4-tetrafluoro-4H-benzo[1,3]dioxin-6-yl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
Gastric inhibitory polypeptide receptor
Protein (Entity type)
IC50

(3S,6S,9S,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54S,57S,66S)-12-((1H-indol-3-yl)methyl)-57-((2S,5S,8S,11S,14S,20S,26S)-26-amino-20-(3-amino-3-oxopropyl)-11-benzyl-2-(carboxymethyl)-8,14-bis((R)-1-hydroxyethyl)-5-(hydroxymethyl)-27-(1H-imidazol-5-yl)-23,23-dimethyl-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazaheptacosanamido)-3-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-ylcarbamoyl)-36-(3-amino-3-oxopropyl)-27,51-bis(4-aminobutyl)-21-benzyl-18-sec-butyl-24,39-bis(2-carboxyethyl)-42-(carboxymethyl)-48-(4-hydroxybenzyl)-54-(hydroxymethyl)-6,9,45-triisobutyl-15,30,33-trimethyl-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,63-nonadecaoxo-66-palmitamido-4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,62-nonadecaazaheptahexacontane-1,67-dioic acid
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
Gastric inhibitory polypeptide receptor
Protein (Entity type)
EC50

(R)-3-{4-[1-(4-Cyclohexylphenyl)-3-(4-trifluoromethylsulfanylphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
Gastric inhibitory polypeptide receptor
Protein (Entity type)
IC50

(R)-3-{4-[1-(4-Cyclohexylphenyl)-3-(3,5-dichlorophenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
Gastric inhibitory polypeptide receptor
Protein (Entity type)
IC50

(3S,6S,9S,12S,15S,18S,21S)-3-((3S,6S,9S,12S,21S)-21-((2R,3S,6S,9S,12S,15S,18S,21S,24S,27S)-15-((1H-indol-3-yl)methyl)-6-(2-amino-2-oxoethyl)-24-benzyl-21-sec-butyl-3-carbamoyl-29-carboxy-2-hydroxy-12-isobutyl-18-methyl-9-(2-(methylthio)ethyl)-5,8,11,14,17,20,23,26-octaoxo-4,7,10,13,16,19,22,25-octaazanonacosan-27-ylcarbamoyl)-9-(3-amino-3-oxopropyl)-3,6-dimethyl-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentaazacyclohenicosan-12-ylcarbamoyl)-21-((2S,5S,8S,11S,17S,20S,23S)-23-amino-17-(3-amino-3-oxopropyl)-8-benzyl-5,11-bis((R)-1-hydroxyethyl)-2,20-bis(hydroxymethyl)-24-(1H-imidazol-5-yl)-4,7,10,13,16,19,22-heptaoxo-3,6,9,12,15,18,21-heptaazatetracosanamido)-12-(4-aminobutyl)-9,18-bis(4-hydroxybenzyl)-15-(hydroxymethyl)-6-isobutyl-5,8,11,14,17,20-hexaoxo-4,7,10,13,16,19-hexaazatricosane-1,23-dioic acid
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
Gastric inhibitory polypeptide receptor
Protein (Entity type)
EC50

Gastric inhibitory polypeptide receptor
Protein (Entity type)
Has isoform
Knowledge Graph Relation (Entity type)
UNIPROTKB.ISOFORM:P48546-1 CUI
Isoform (Entity type)

(3S,6S,9S,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54S,57S,66S)-12-((1H-indol-3-yl)methyl)-3-(2-((S)-1-(2-amino-2-oxoethylamino)-5-guanidino-1-oxopentan-2-ylamino)-2-oxoethylcarbamoyl)-57-((2S,5S,8S,11S,14S,20S,26S)-26-amino-20-(3-amino-3-oxopropyl)-11-benzyl-2-(carboxymethyl)-8,14-bis((R)-1-hydroxyethyl)-5-(hydroxymethyl)-27-(1H-imidazol-5-yl)-23,23-dimethyl-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazaheptacosanamido)-15,27-bis(3-amino-3-oxopropyl)-51-(4-aminobutyl)-21-benzyl-39-(2-carboxyethyl)-24,42-bis(carboxymethyl)-36-(3-guanidinopropyl)-48-(4-hydroxybenzyl)-54-(hydroxymethyl)-6,9,45-triisobutyl-18-isopropyl-30,33-dimethyl-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,63-nonadecaoxo-66-palmitamido-4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,62-nonadecaazaheptahexacontane-1,67-dioic acid
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
Gastric inhibitory polypeptide receptor
Protein (Entity type)
EC50

(3S,6S,9S,12S,15S,18S,21S)-3-((3S,6S,9S,12S,21S)-6-((1H-imidazol-5-yl)methyl)-21-((2R,3S,6S,9S,12S,15S,18S,21S,24S,27S)-15-((1H-indol-3-yl)methyl)-6-(2-amino-2-oxoethyl)-24-benzyl-21-sec-butyl-3-carbamoyl-29-carboxy-2-hydroxy-12-isobutyl-18-methyl-9-(2-(methylthio)ethyl)-5,8,11,14,17,20,23,26-octaoxo-4,7,10,13,16,19,22,25-octaazanonacosan-27-ylcarbamoyl)-3-(3-amino-3-oxopropyl)-9-sec-butyl-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentaazacyclohenicosan-12-ylcarbamoyl)-21-((2S,5S,8S,11S,17S,20S,23S)-23-amino-17-(3-amino-3-oxopropyl)-8-benzyl-5,11-bis((R)-1-hydroxyethyl)-2,20-bis(hydroxymethyl)-24-(1H-imidazol-5-yl)-4,7,10,13,16,19,22-heptaoxo-3,6,9,12,15,18,21-heptaazatetracosanamido)-12-(4-aminobutyl)-9,18-bis(4-hydroxybenzyl)-15-(hydroxymethyl)-6-isobutyl-5,8,11,14,17,20-hexaoxo-4,7,10,13,16,19-hexaazatricosane-1,23-dioic acid
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
Gastric inhibitory polypeptide receptor
Protein (Entity type)
EC50

(4S,7S,10S,13S,16S,19S,22S,25S,28S,31S,34S,37S,46S)-4-((2S,5S,8S,11S,14S,17S,20S,23S,24R)-11-((1H-indol-3-yl)methyl)-20-(2-amino-2-oxoethyl)-5-sec-butyl-23-carbamoyl-24-hydroxy-14-isobutyl-8-methyl-17-(2-(methylthio)ethyl)-3,6,9,12,15,18,21-heptaoxo-1-phenyl-4,7,10,13,16,19,22-heptaazapentacosan-2-ylcarbamoyl)-37-((2S,5S,8S,11S,14S,20S,23R,26S)-26-amino-20-(3-amino-3-oxopropyl)-11-benzyl-2-(carboxymethyl)-8,14-bis((R)-1-hydroxyethyl)-5,23-bis(hydroxymethyl)-27-(1H-imidazol-5-yl)-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazaheptacosanamido)-16-(3-amino-3-oxopropyl)-7,31-bis(4-aminobutyl)-19-(2-carboxyethyl)-22-(carboxymethyl)-28-(4-hydroxybenzyl)-34-(hydroxymethyl)-25-isobutyl-10,13-dimethyl-6,9,12,15,18,21,24,27,30,33,36,43-dodecaoxo-46-palmitamido-5,8,11,14,17,20,23,26,29,32,35,42-dodecaazaheptatetracontane-1,47-dioic acid
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
Gastric inhibitory polypeptide receptor
Protein (Entity type)
EC50

DISPLAY PER PAGE

Knowledge Graph Assertions

	Source	Relation	Target	Evidence
Loading results...

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2025

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.